KLRS
Kalaris Therapeutics Inc
Biotechnology
Market Cap$81M
5Y Perf.-46.1%
Build Your Comparison
Side-by-side financial analysisKLRS
REPL
Try popular comparisons:
Stock Comparison
KLRS vs REPL
Revenue, margins, valuation, and 5-year total return — side by side.
REPL
Replimune Group, Inc.
Biotechnology
Market Cap$733M
5Y Perf.-8.9%
KLRS vs REPL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  KLRS |  REPL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $81M | $733M |
| Revenue (TTM) | $0.00 | — |
| Net Income (TTM) | $-44M | $-315M |
| Total Debt | $1M | $76M |
| Cash & Equiv. | $98M | $111M |
KLRS vs REPL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KLRS
REPL
| Stock | Mar 25 | Jun 26 | Return |
|---|---|---|---|
| Kalaris Therapeutic… (KLRS) | 100 | 53.9 | -46.1% |
| Replimune Group, In… (REPL) | 100 | 91.1 | -8.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KLRS vs REPL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KLRS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Replimune Group, Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇KLRS emerged as the overall leader. Track its performance:
KLRS
Kalaris Therapeutics Inc
The Income Pick
KLRS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.81
- EPS growth 75.7%
- Lower volatility, beta 0.81, Low D/E 1.8%, current ratio 12.23x
Best for: income & stability and growth exposure
REPL
Replimune Group, Inc.
The Long-Run Compounder
REPL is the clearest fit if your priority is long-term compounding.
- -41.4% 10Y total return vs KLRS's -52.5%
- 2.4% margin vs KLRS's -1.2%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  KLRS | 100.0% revenue growth vs REPL's -39.7% |
| Quality / Margins |  REPL | 2.4% margin vs KLRS's -1.2% |
| Stability / Safety | KLRS | Beta 0.81 vs REPL's 0.84, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KLRS | +56.9% vs REPL's -10.2% |
| Efficiency (ROA) | KLRS | -43.5% ROA vs REPL's -72.2% |
KLRS vs REPL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKLRSLAGGINGREPL
REPLReplimune Group, Inc.
0leads
KLRSKalaris Therapeutics …
3leads
6 Total Categories
CATEGORYLEADERvs REPLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KLRS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KLRS8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
KLRS4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KLRS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … |
|---|---|---|
| RevenueTrailing 12 months | $0 | — |
| EBITDAEarnings before interest/tax | -$46M | -$323M |
| Net IncomeAfter-tax profit | -$44M | -$315M |
| Free Cash FlowCash after capex | -$49M | -$283M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +81.7% | +2.5% |
KLRS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KLRS and REPL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … |
|---|---|---|
| Market CapShares × price | $81M | $733M |
| Enterprise ValueMkt cap + debt − cash | -$16M | $698M |
| Trailing P/EPrice ÷ TTM EPS | -1.52x | -2.89x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.84x | 1.72x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KLRS and REPL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
KLRS leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
KLRS delivers a -72.8% return on equity — every $100 of shareholder capital generates $-73 in annual profit, vs $-103 for REPL. KLRS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to REPL's 0.18x. On the Piotroski fundamental quality scale (0–9), KLRS scores 3/9 vs REPL's 2/9, reflecting mixed financial health.
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … |
|---|---|---|
| ROE (TTM)Return on equity | -72.8% | -102.7% |
| ROA (TTM)Return on assets | -43.5% | -72.2% |
| ROICReturn on invested capital | — | -51.9% |
| ROCEReturn on capital employed | -41.0% | -55.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.18x |
| Net DebtTotal debt minus cash | -$97M | -$35M |
| Cash & Equiv.Liquid assets | $98M | $111M |
| Total DebtShort + long-term debt | $1M | $76M |
| Interest CoverageEBIT ÷ Interest expense | -31.98x | -48.62x |
KLRS leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
KLRS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KLRS five years ago would be worth $4,748 today (with dividends reinvested), compared to $2,561 for REPL. Over the past 12 months, KLRS leads with a +56.9% total return vs REPL's -10.2%. The 3-year compound annual growth rate (CAGR) favors KLRS at -22.0% vs REPL's -27.7% — a key indicator of consistent wealth creation.
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … |
|---|---|---|
| YTD ReturnYear-to-date | -47.8% | -0.2% |
| 1-Year ReturnPast 12 months | +56.9% | -10.2% |
| 3-Year ReturnCumulative with dividends | -52.5% | -62.1% |
| 5-Year ReturnCumulative with dividends | -52.5% | -74.4% |
| 10-Year ReturnCumulative with dividends | -52.5% | -41.4% |
| CAGR (3Y)Annualised 3-year return | -22.0% | -27.7% |
KLRS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KLRS and REPL each lead in 1 of 2 comparable metrics.
Risk & Volatility
KLRS is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than REPL's 0.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REPL currently trades 67.1% from its 52-week high vs KLRS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 0.84x |
| 52-Week HighHighest price in past year | $11.88 | $13.24 |
| 52-Week LowLowest price in past year | $2.14 | $1.50 |
| % of 52W HighCurrent price vs 52-week peak | +36.4% | +67.1% |
| RSI (14)Momentum oscillator 0–100 | 39.7 | 63.4 |
| Avg Volume (50D)Average daily shares traded | 86K | 8.9M |
Evenly matched — KLRS and REPL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Consensus price targets imply 331.2% upside for KLRS (target: $19) vs 57.7% for REPL (target: $14).
| Metric | KLRSKalaris Therapeut… | REPLReplimune Group, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | $18.67 | $14.00 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KLRS leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallKalaris Therapeutics Inc (KLRS)Leads 3 of 6 categories
Loading custom metrics...
KLRS vs REPL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KLRS or REPL a better buy right now?
Analysts rate Replimune Group, Inc.
(REPL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KLRS or REPL?
Over the past 5 years, Kalaris Therapeutics Inc (KLRS) delivered a total return of -52.
5%, compared to -74. 4% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: REPL returned -41. 4% versus KLRS's -52. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KLRS or REPL?
By beta (market sensitivity over 5 years), Kalaris Therapeutics Inc (KLRS) is the lower-risk stock at 0.
81β versus Replimune Group, Inc. 's 0. 84β — meaning REPL is approximately 3% more volatile than KLRS relative to the S&P 500. On balance sheet safety, Kalaris Therapeutics Inc (KLRS) carries a lower debt/equity ratio of 2% versus 18% for Replimune Group, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KLRS or REPL?
On earnings-per-share growth, the picture is similar: Kalaris Therapeutics Inc grew EPS 75.
7% year-over-year, compared to 5. 2% for Replimune Group, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KLRS or REPL?
Kalaris Therapeutics Inc (KLRS) is the more profitable company, earning 0.
0% net margin versus 0. 0% for Replimune Group, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KLRS leads at 0. 0% versus 0. 0% for REPL. At the gross margin level — before operating expenses — KLRS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KLRS or REPL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KLRS or REPL better for a retirement portfolio?
For long-horizon retirement investors, Kalaris Therapeutics Inc (KLRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
81)). Both have compounded well over 10 years (KLRS: -52. 5%, REPL: -41. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KLRS and REPL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.